---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-024939"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2023-02-24T23:59:59+00:00"
generated_at: "2026-06-19T00:47:14.860512+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Voyager closes Neurocrine collaboration, receives $175M; Neurocrine CSO joins board

## Summary
- Collaboration Agreement effective; Neurocrine pays $136M upfront.
- Neurocrine buys 4,395,588 shares at $8.88/share for ~$39M.
- Jude Onyia, Ph.D., Neurocrine's CSO, appointed to board effective closing.
- Onyia designated Class III director until 2024 annual meeting; Neurocrine retains nomination right while holding ≥10%.
- Onyia receives standard non-employee director compensation: $40K cash retainer, initial option for 44,000 shares, annual option for 22,000 shares.

## SEC filing metadata
- accession: 0001104659-23-024939
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2023-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465923024939/0001104659-23-024939-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465923024939/tm237527d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-024939
- JSON: https://secwatch.observer/filing/0001104659-23-024939.json
- Plain text: https://secwatch.observer/filing/0001104659-23-024939.txt

## Key facts
- Executive change
  Jude Onyia, Ph.D. was appointed as director at Voyager Therapeutics, Inc..
  - Action: appointed
  - Role: director
  source text: the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), approved the appointment of Jude Onyia, Ph.D., to serve as a director of the Company, contingent upon and effective as of the closing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000110465923024939/0001104659-23-024939-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.